All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Did you miss ASH 2018? The Lymphoma Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA and has developed a downloadable resource, which provides information on the practice changing abstracts across lymphoma and CLL.
Our selection of ASH 2018 abstracts include comments from The Lymphoma Hub Steering Committee members Stefano Luminari and Gilles Salles on ibrutinib combination therapies for the front-line treatment of CLL, and the role of the lenalidomide and rituximab combination in relapsed follicular lymphoma. Hear from the experts on the role of mutations that confer resistance to venetoclax and whether less is more when it comes to front line treatment in patients with DLBCL.
ASH 2018 | Practice changing abstracts in non-Hodgkin lymphoma and chronic lymphocytic leukemia
If you would like to view the ASH 2018 highlights, practice changing abstracts and expert opinions please find the Lymphoma Hub resource below:Download Here
ASCO 2018 | The Highlights
Did you miss ASCO 2018? The Lymphoma Hub has developed a downloadable resource which provides a summary of the key presentations in lymphoma and CLL at the ASCO 2018 annual meeting, Chicago, June 1-5
Bruce Cheson | ASCO 2018 | Potential for chemotherapy-free future in lymphoid malignancies
Bruce Cheson | ASCO 18 | Potential for chemotherapy-free future in lymphoid malignancies
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox